Cipla - Launch of CIPtest - Angel Broking
Posted On:
Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd
Cipla Ltd stock up by 0.3% on Launches CIPtest Rapid Antigen Detection Test for COVID-19 Diagnosis. Cipla Limited today announced its partnership with the Premier Medical Corporation Private Limited for commercialization of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week. This is Cipla s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit. In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Private Limited. The test is a rapid point-of-care nasopharyngeal swab test that directly detects the presence or absence of coronavirus antigen in the patient s body, generating results within 15-20 minutes. CIPtest is a re
Cipla launches rapid antigen test kits for COVID-19
Cipla launches rapid antigen test kits for COVID-19
16 December 2020 | News The test is a rapid point-of-care nasopharyngeal swab test that directly detects the presence or absence of coronavirus antigen in the patient’s body, generating results within 15-20 minutes
Image Credit: shutterstock.com
Cipla has announced its partnership with the Premier Medical Corporation Private Limited for commercialisation of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week.
This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit. In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Private Limited.
Cipla Launches CIPtest Rapid Antigen Detection Test for COVID-19 Diagnosis
Posted On: 2020-12-15 21:38:34 (Time Zone: Arizona, USA)
Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as Cipla today announced its partnership with the Premier Medical Corporation Private Limited for commercialisation of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week.
This is Cipla s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit. In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Private Limited.
Cipla launches rapid antigen test for Covid-19 diagnosis daijiworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from daijiworld.com Daily Mail and Mail on Sunday newspapers.
Cipla launches rapid antigen detection CIPtest for COVID-19 diagnosis
Rapid antigen detection test directly detects presence or absence of coronavirus antigen in patient s body, generating results in 15-20 minutes; ICMR-approved CIPtest is found to have specificity and sensitivity of 98.09 per cent and up to 75 per cent
BusinessToday.In | December 16, 2020 | Updated 14:46 IST
Cipla s extensive distribution network will help in ensuring supply of kits across country
After Elifast ELISA test kit, drug major Cipla has said it ll partner with Premier Medical Corporation Private Limited to produce rapid antigen COVID-19 testing kits in India. While Premier Medical Corporation Private will make the kits, Cipla will be responsible for marketing and distribution of the rapid antigen detection test kit that s used for the detection of coronavirus antigen. The testing kit will be marketed under the brand name CIPtest .